TECH - バイオテクネ (Bio-Techne Corp) バイオテクネ

 TECHのチャート


 TECHの企業情報

symbol TECH
会社名 Bio-Techne Corp (バイオテクネ)
分野(sector) Health Care   ヘルスケア
産業(industry) Biotechnology: Biological Products (No Diagnostic Substances)  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 バイオ・テクネ(Bio-Techne Corp)(旧名:TECHNE Corporation)はバイオテクノロジー製品、血液学校正器及びコントロールの開発・生産・販売に従事する企業である。同社は完全子会社Research and Diagnostic Systems Inc.、Boston Biochem Inc及びBiosPacific Inc.を通して事業を展開している。同社はバイオテクノロジー事業及び血液学事業の2つの部門を通して運営する。バイオテクノロジー事業部門は世界中においてバイオテクノロジーの研究・診断製品を開発・製造・販売する。血液学事業は研究・開発システム血液学区分により構成され、世界中において血液学コントロール・校正器を開発・製造する。   バイオテクネは米国のバイオテクノロジ―製品メ―カ―。バイオテクノロジ―製品および臨床診断管理製品を開発、製造、販売する。バイオテクノロジ―部門はバイオテクノロジ―研究と診断製品の開発、製造、販売を手掛ける。診断管理製品部門は臨床市場向けにコントロ―ル試薬および測定器を提供。   Bio-Techne Corporation is a holding company for biotechnology and clinical diagnostic brands. It was founded in 1976 as Techne Corporation and changed its name to Bio-Techne in 2014.
本社所在地 614 McKinley Place N.E. Minneapolis MN 55413 USA
代表者氏名 Robert V. Baumgartner Robert V. Baumgartner
代表者役職名 Independent Chairman of the Board
電話番号 +1 612-379-8854
設立年月日 1976年
市場名 NASDAQ National Market System
ipoyear ―年
従業員数 2000人
url www.bio-techne.com
nasdaq_url https://www.nasdaq.com/symbol/tech
adr_tso
EBITDA EBITDA(百万ドル) 222.61500
終値(lastsale) 189.31
時価総額(marketcap) 7148019040.25
時価総額 時価総額(百万ドル) 7118.567
売上高 売上高(百万ドル) 642.99300
企業価値(EV) 企業価値(EV)(百万ドル) 7275.813
当期純利益 当期純利益(百万ドル) 92.94900
決算概要 決算概要 BRIEF: For the fiscal year ended 30 June 2018 BIO-TECHNE Corp revenues increased 14% to $643M. Net income before extraordinary items increased 22% to $93M. Revenues reflect Biotechnology segment increase of 16% to $421.5M Protein Platforms segment increase of 22% to $111.9M Diagnostics segment increase of 3% to $110.1M United States segment increase of 11% to $346.3M Europe_Middle East segment increase of 19% to $148.6M.

 TECHのテクニカル分析


 TECHのニュース

   The Daily Biotech Pulse: Cellect Jumps On First Apograft Transplantation, AstraZeneca, European Commission Bury Legal Hatchet, Cassava Defends Itself  2021/09/03 11:31:12 Benzinga
Here''s a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 2) Abbott Laboratories (NYSE: ABT ) (announced acquisition of medical device company Walk Vascular) Adagio Therapeutics, Inc. (NASDAQ: ADGI ) (IPOed Aug. 6) Axonics, Inc. (NASDAQ: AXNX ) Bicycle Therapeutics plc (NASDAQ: BCYC ) Bio-Rad Laboratories, Inc. (NYSE: BIO ) Bio-Techne Corporation (NASDAQ: TECH ) Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN ) Catalent, Inc. (NASDAQ: CTLT ) Celldex Therapeutics, Inc. (NASDAQ: CLDX ) Cerevel Therapeutics Holdings, Inc. (NASDAQ: CERE ) Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX ) (announced COO appointment) Cryo-Cell International, Inc. (NASDAQ: CCEL ) (announced uplisting to Nasdaq on Tuesday) DexCom, Inc. (NASDAQ: DXCM ) Edwards Lifesciences Corporation (NYSE: EW ) Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA ) Erasca, Inc. (NASDAQ: ERAS ) Genmab A/S (NASDAQ: GMAB ) Globus Medical, Inc. (NYSE: GMED ) Intuitive Surgical, Inc.
   The Daily Biotech Pulse: VectivBio In M&A Mix, Sonnet Biotherapeutics Advances Candidate To Clinics, CEO Transitions At Galapagos, Talis Biomedical  2021/08/31 12:05:06 Benzinga
Here''s a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 26) Agenus Inc. (NASDAQ: AGEN ) Alkermes plc (NASDAQ: ALKS ) Axonics, Inc. (NASDAQ: AXNX ) Bio-Techne Corporation (NASDAQ: TECH ) BioLife Solutions, Inc. (NASDAQ: BLFS ) Bio-Rad Laboratories, Inc. (NYSE: BIO ) Celldex Therapeutics, Inc. (NASDAQ: CLDX ) Cerevel Therapeutics Holdings, Inc. (NASDAQ: CERE ) Clearside Biomedical, Inc. (NASDAQ: CLSD ) Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX ) Cytokinetics, Incorporated (NASDAQ: CYTK ) Dermata Therapeutics, Inc. (NASDAQ: DRMA ) Dynavax Technologies Corporation (NASDAQ: DVAX ) Eliem Therapeutics, Inc. (NASDAQ: ELYM ) (IPOed Aug. 10) Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA ) IVERIC bio, Inc. (NASDAQ: ISEE ) Kezar Life Sciences, Inc. (NASDAQ: KZR ) Merit Medical Systems, Inc. (NASDAQ: MMSI ) MiMedx Group, Inc. (NASDAQ: MDXG ) PDS Biotechnology Corporation (NASDAQ: PDSB ) Pieris Pharmaceuticals, Inc.
   Mesenchymal Stem Cells Market 2021 Future Development, Vital Challenges and Forecast Analysis By 2026|Lonza, Thermo Fisher, Bio-Techne, ATCC  2021/08/27 06:04:23 OpenPR
The Mesenchymal Stem Cells Market report is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, inputs from industry experts, and industry participants across the value chain. The report provides an in-depth analysis of parent market trends,
   Heres Why Baron Funds Remains Confident in Bio-Techne Corporation (TECH)  2021/08/18 17:18:15 Insider Monkey
   Bio-techne Corp (TECH) CFO James Hippel Sold $4.8 million of Shares  2021/08/11 20:15:04 GuruFocus
Related Stocks: TECH ,
   The Daily Biotech Pulse: Cellect Jumps On First Apograft Transplantation, AstraZeneca, European Commission Bury Legal Hatchet, Cassava Defends Itself  2021/09/03 11:31:12 Benzinga
Here''s a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 2) Abbott Laboratories (NYSE: ABT ) (announced acquisition of medical device company Walk Vascular) Adagio Therapeutics, Inc. (NASDAQ: ADGI ) (IPOed Aug. 6) Axonics, Inc. (NASDAQ: AXNX ) Bicycle Therapeutics plc (NASDAQ: BCYC ) Bio-Rad Laboratories, Inc. (NYSE: BIO ) Bio-Techne Corporation (NASDAQ: TECH ) Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN ) Catalent, Inc. (NASDAQ: CTLT ) Celldex Therapeutics, Inc. (NASDAQ: CLDX ) Cerevel Therapeutics Holdings, Inc. (NASDAQ: CERE ) Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX ) (announced COO appointment) Cryo-Cell International, Inc. (NASDAQ: CCEL ) (announced uplisting to Nasdaq on Tuesday) DexCom, Inc. (NASDAQ: DXCM ) Edwards Lifesciences Corporation (NYSE: EW ) Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA ) Erasca, Inc. (NASDAQ: ERAS ) Genmab A/S (NASDAQ: GMAB ) Globus Medical, Inc. (NYSE: GMED ) Intuitive Surgical, Inc.
   The Daily Biotech Pulse: VectivBio In M&A Mix, Sonnet Biotherapeutics Advances Candidate To Clinics, CEO Transitions At Galapagos, Talis Biomedical  2021/08/31 12:05:06 Benzinga
Here''s a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 26) Agenus Inc. (NASDAQ: AGEN ) Alkermes plc (NASDAQ: ALKS ) Axonics, Inc. (NASDAQ: AXNX ) Bio-Techne Corporation (NASDAQ: TECH ) BioLife Solutions, Inc. (NASDAQ: BLFS ) Bio-Rad Laboratories, Inc. (NYSE: BIO ) Celldex Therapeutics, Inc. (NASDAQ: CLDX ) Cerevel Therapeutics Holdings, Inc. (NASDAQ: CERE ) Clearside Biomedical, Inc. (NASDAQ: CLSD ) Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX ) Cytokinetics, Incorporated (NASDAQ: CYTK ) Dermata Therapeutics, Inc. (NASDAQ: DRMA ) Dynavax Technologies Corporation (NASDAQ: DVAX ) Eliem Therapeutics, Inc. (NASDAQ: ELYM ) (IPOed Aug. 10) Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA ) IVERIC bio, Inc. (NASDAQ: ISEE ) Kezar Life Sciences, Inc. (NASDAQ: KZR ) Merit Medical Systems, Inc. (NASDAQ: MMSI ) MiMedx Group, Inc. (NASDAQ: MDXG ) PDS Biotechnology Corporation (NASDAQ: PDSB ) Pieris Pharmaceuticals, Inc.
   Mesenchymal Stem Cells Market 2021 Future Development, Vital Challenges and Forecast Analysis By 2026|Lonza, Thermo Fisher, Bio-Techne, ATCC  2021/08/27 06:04:23 OpenPR
The Mesenchymal Stem Cells Market report is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, inputs from industry experts, and industry participants across the value chain. The report provides an in-depth analysis of parent market trends,
   Heres Why Baron Funds Remains Confident in Bio-Techne Corporation (TECH)  2021/08/18 17:18:15 Insider Monkey
   Bio-techne Corp (TECH) CFO James Hippel Sold $4.8 million of Shares  2021/08/11 20:15:04 GuruFocus
Related Stocks: TECH ,
   Exosome Diagnostics and Therapeutic Market to Eyewitness Massive Revenue Growth of US$ 358.91 million with a Healthy CAGR 32.2% from 2020 to 2027 | Evomic Science LLC, NorgenBiotek Corp, Exosome Diagnostics, Inc./Bio-Techne,, MiltenyiBiotec  2021/08/09 09:59:14 OpenPR
The Exosome Diagnostics and Therapeutic Market was valued at US$ 41.6.33 million in 2019 and is expected to grow at a CAGR of 32.2% from 2020 to 2027 to reach US$ 358.91 million 2027. Exosomes are nano-vesicles that constitute proteins, DNA,
   Bio-Techne Corporation (TECH) CEO Chuck Kummeth on Q4 2021 Results - Earnings Call Transcript  2021/08/07 16:09:15 Seeking Alpha
   Bio-Techne declares $0.32 dividend  2021/08/05 10:34:44 Seeking Alpha
   Bio-Techne EPS beats by $0.17, beats on revenue  2021/08/05 10:33:26 Seeking Alpha
   How Have the Numbers Shaped Up for Bio-Techne (NASDAQ:TECH)  2021/08/04 17:48:00 Stock Market Daily
Earnings results for Bio-Techne , Analyst Opinion on Bio-Techne , Earnings and Valuation of (NASDAQ:TECH), Stock market Insights & financial analysis, Best stock to invest, Investment Idea, The post How Have the Numbers Shaped Up for Bio-Techne (NASDAQ:TECH) appeared first on .

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 バイオテクネ TECH Bio-Techne Corp)

 twitter  (公式ツイッターやCEOツイッターなど)